These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30215805)

  • 1. Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.
    Bryant RV; Schultz CG; Ooi S; Goess C; Costello SP; Vincent AD; Schoeman S; Lim A; Bartholomeusz FD; Travis SPL; Andrews JM
    Inflamm Bowel Dis; 2019 Feb; 25(3):592-600. PubMed ID: 30215805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.
    Van Der Sloot KW; Joshi AD; Bellavance DR; Gilpin KK; Stewart KO; Lochhead P; Garber JJ; Giallourakis C; Yajnik V; Ananthakrishnan AN; Alizadeh BZ; Xavier RJ; Khalili H
    Inflamm Bowel Dis; 2017 Jan; 23(1):82-88. PubMed ID: 27893544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease.
    Uko V; Vortia E; Achkar JP; Karakas P; Fiocchi C; Worley S; Kay MH
    Inflamm Bowel Dis; 2014 Dec; 20(12):2286-91. PubMed ID: 25222655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral adiposity predicts post-operative Crohn's disease recurrence.
    Holt DQ; Moore GT; Strauss BJ; Hamilton AL; De Cruz P; Kamm MA
    Aliment Pharmacol Ther; 2017 May; 45(9):1255-1264. PubMed ID: 28244124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.
    Dai C; Jiang M; Huang YH
    Inflamm Bowel Dis; 2019 May; 25(6):e61. PubMed ID: 30380063
    [No Abstract]   [Full Text] [Related]  

  • 7. Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not.
    Sehgal P; Su S; Zech J; Nobel Y; Luk L; Economou I; Shen B; Lewis JD; Freedberg DE
    Inflamm Bowel Dis; 2024 Apr; 30(4):594-601. PubMed ID: 37307420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life.
    Bryant RV; Schultz CG; Ooi S; Goess C; Costello SP; Vincent AD; Schoeman S; Lim A; Bartholomeusz FD; Travis SPL; Andrews JM
    Inflamm Bowel Dis; 2019 May; 25(6):e62-e63. PubMed ID: 30380064
    [No Abstract]   [Full Text] [Related]  

  • 10. Visceral Adipose Tissue in Patients with Crohn's Disease Correlates with Disease Activity, Inflammatory Markers, and Outcome.
    Büning C; von Kraft C; Hermsdorf M; Gentz E; Wirth EK; Valentini L; Haas V
    Inflamm Bowel Dis; 2015 Nov; 21(11):2590-7. PubMed ID: 26222339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
    Cerrillo E; Moret I; Iborra M; Pamies J; Hervás D; Tortosa L; Sáez-González E; Nos P; Beltrán B
    Inflamm Bowel Dis; 2019 Sep; 25(10):1681-1691. PubMed ID: 30925193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.
    Li X; Zhang N; Hu C; Lin Y; Li J; Li Z; Cui E; Shi L; Zhuang X; Li J; Lu J; Wang Y; Liu R; Yuan C; Lin H; He J; Ke D; Tang S; Zou Y; He B; Sun C; Chen M; Huang B; Mao R; Feng ST
    EClinicalMedicine; 2023 Feb; 56():101805. PubMed ID: 36618894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis.
    Murray KA; Hoad CL; Garratt J; Kaviani M; Marciani L; Smith JK; Siegmund B; Gowland PA; Humes DJ; Spiller RC
    PLoS One; 2019; 14(5):e0216528. PubMed ID: 31067253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease.
    Pous-Serrano S; Frasson M; Cerrillo E; Beltrán B; Iborra M; Hervás D; García-Granero E; Nos P
    J Surg Res; 2017 Jun; 213():290-297. PubMed ID: 28601328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
    Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
    J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Composition Predictors of Complicated Crohn's Disease.
    Barajas Ordonez F; Melekh B; Rodríguez-Feria P; Melekh O; Thormann M; Damm R; Omari J; Pech M; Surov A
    Dig Dis; 2023; 41(4):589-599. PubMed ID: 36720207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease.
    Shaoul R; Sladek M; Turner D; Paeregaard A; Veres G; Wauters GV; Escher J; Dias JA; Lionetti P; Staino A; Kolho KL; de Ridder L; Nuti F; Cucchiara S; Sheva O; Levine A;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1493-7. PubMed ID: 22275268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.